Alzheimer's is a neurodegenerative disease caused by the accumulation and extracellular deposition of the amyloid beta protein in the hippocampus. This process results in neuronal death, leading to memory impairment and progressive cognitive decline. Aging is the main risk factor for the development of Alzheimer's, and the hippocampus is severely affected in this condition. Recent studies show that insulin resistance in the nervous system, reduced glucose utilization and deficiencies in energy metabolism are often found in Alzheimer's and elderly individuals. In this context, tauroursodeoxycholic bile acid (TUDCA) has been used in neurodegenerative disease models, because it has antiapoptotic properties, besides acting in metabolic pathways, modulating insulin secretion and signaling, as well as endoplasmic reticulum stress. In Alzheimer's disease, TUDCA treatment reduces the accumulation of amyloid beta plaques in APP/PS1 transgenic mice, attenuating the damage caused by this disease, through a mechanism not yet fully elucidated. In this work, using C57BL/6 mice that will receive intracerebroventricular injection of streptozotocin for induction of Alzheimer's, as well as senile mice, both treated with 300 mg/kg of intraperitoneal TUDCA, we aimed to evaluate the role of this bile acid in the glycemic and energetic metabolism of these experimental models, analyzing behavioral, molecular and metabolic markers characteristic of the disease. This project will contribute to understanding the metabolic and molecular parameters that are altered in mice with Alzheimer's and senile, as well as potential elucidation of the signaling pathways in which the bile acid TUDCA participates, seeking possible preventive methods and treatments for Alzheimer's and cognitive impairment due to aging.
News published in Agência FAPESP Newsletter about the scholarship: